Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

J&J negotiates to buy Actelion

by Ann M. Thayer
December 5, 2016 | A version of this story appeared in Volume 94, Issue 48

Johnson & Johnson and Switzerland’s Actelion Pharmaceuticals confirm that they have held preliminary discussions about a potential transaction. According to news reports, J&J has made two bids well above Actelion’s current market value of about $21 billion. The nearly 20-year-old Swiss firm is recognized for its development of endothelin receptor antagonists, which include the pulmonary arterial hypertension drug Tracleer and newer potential PAH blockbusters Opsumit and Uptravi. For the first nine months of 2016, Actelion had sales of $1.75 billion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.